Yasuda Enterprise Development

Total investments

43

Average round size

16M

Portfolio companies

30

Rounds per year

1.87

Lead investments

1

Follow on index

0.30

Exits

18

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyInformation TechnologyHealth CareManufacturingMedicalPharmaceuticalHardwareSemiconductorElectronicsBiopharma

Summary

In 1999 was created Yasuda Enterprise Development, which is appeared as VC. The company was established in North America in United States. The main department of described VC is located in the Menlo Park.

We can highlight the next thriving fund investment areas, such as Pharmaceutical, Hardware. The fund has exact preference in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Synageva BioPharma, Topica Pharmaceuticals, InPhase Technologies. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Comparing to the other companies, this Yasuda Enterprise Development performs on 10 percentage points more the average number of lead investments. The average startup value when the investment from Yasuda Enterprise Development is 50-100 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2004. The fund is constantly included in less than 2 deals per year. The top amount of exits for fund were in 2013.

The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Yasuda Enterprise Development, startups are often financed by Oxford Bioscience Partners, Kleiner Perkins, HealthCare Ventures. The meaningful sponsors for the fund in investment in the same round are Japan Asia Investment, HealthCare Ventures, NIF Ventures. In the next rounds fund is usually obtained by Japan Asia Investment, Kleiner Perkins, SMBC Venture Capital.

Show more

Investments analytics

Analytics

Total investments
43
Lead investments
1
Exits
18
Rounds per year
1.87
Follow on index
0.30
Investments by industry
  • Biotechnology (18)
  • Health Care (11)
  • Pharmaceutical (10)
  • Medical (10)
  • Information Technology (7)
  • Show 41 more
Investments by region
  • United States (23)
  • Japan (15)
  • United Kingdom (3)
  • Switzerland (1)
Peak activity year
2005
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
20
Avg. valuation at time of investment
299M
Group Appearance index
0.98
Avg. company exit year
12
Avg. multiplicator
7.20
Strategy success index
0.20

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Bizon 03 Mar 2020 E-Commerce, Internet, Retail Technology, Digital Marketing, Marketing, Consulting, Brand Marketing Seed 295K Ile-de-France, Paris, France
HENNGE 28 Sep 2000 Information Technology Early Stage Venture 0 Chiyoda, Japan
18 Dec 2018 Accounting, Software, Financial Services, FinTech, Analytics, SaaS, Big Data, Data Visualization Seed 1M United States, New York
Streetmedia 14 Dec 2009 E-Commerce, Retail Technology, Shopping, Consumer Reviews Seed 455K Chiyoda, Japan

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.